Table 2.
Oncolytic viroimmunotherapy for colon cancer in clinical trials.
| Authors & Year | Vector | Phase | N | Delivery | Results | Adverse Effects | Immune Investigations |
|---|---|---|---|---|---|---|---|
| Kemeny & Fong 2006 [88] NCT00149396 |
NV1020 HSV+ GMCSF | I | 12 | 3 × 106 3 × 107 1 × 108 |
GGT rise, diarrhea, elev WBC | TNF-α, IL-2, IL-1, IFN-γ, CD4+/CD8+ ratio | |
| Calvo 2014 [92] NCT02028442 |
Ad11/ad3 Enadenotucirev | I/II | 161 | 1 × 1010–6 × 1012 | No survival data reported yet | Flu-like sx, elevated GGT | Elevated TNF, IFN, IL-6, and IL-12 on Day 1 after higher doses |
| Park SH 2015 [89] NCT01380600 |
JX-594 tk attenuated Vaccinia | Ib | 15 | Up to 4 IV q14 days Dose 1 × 106 pfu/kg, 1 × 107, 3 × 107 |
67% stable disease | Pox skin lesions Flu like symptoms |
IL-2, IL-6, IL-8, IL-10, IL-18, MIP-1α, MCP-1, MIP-1β, and TNF-α |
| Balint 2015 [90] NCT02028442 |
A11/Ad3 group B adenovirus | I/II | 32 | 1 × 109 q3 weeks × 3 1 × 1010 q3 weeks × 3 1 × 1011 q3 weeks × 3 5 × 1011 q3 weeks × 3 |
No objective ant-tumor responses; Median survival 13mos in optimal tx grp |
Injection site rxn Fever, flu-like symptoms |
Cytolytic T cell responses IFN-γ TNF-α |
| NCT01274624 | Reolysin + Folfiri + avastin in Folfiri naïve KRAS mutants | I | 12 | No data reported yet Due Fall 2017 |
|||
| NCT02636036 | Ad11/Ad3 Enadenotucirev + Anti-PD-1 |
I | Study completion June 2019 |